logo
logo
AtriCure, Inc.

AtriCure, Inc.

NASDAQ•ATRC
CEO: Mr. Michael H. Carrel
セクター: Healthcare
業種: Medical - Instruments & Supplies
上場日: 2005-08-05
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
連絡先情報
7555 Innovation Way, Mason, OH, 45040, United States
513-755-4100
www.atricure.com
時価総額
$1.88B
PER (TTM)
-62.7
68
配当利回り
--
52週高値
$43.18
52週安値
$28.29
52週レンジ
64%
順位67Top 97.6%
1.4
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 1.4 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$134.27M+15.84%
直近4四半期の推移

EPS

-$0.01-94.12%
直近4四半期の推移

フリーCF

$24.11M+47.05%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Revenue Growth Strong Worldwide revenue reached $394.03M for nine months, marking a 15.5% increase over prior year period.
Operating Income Achieved Switched to $208K operating income for three months ended September 30, reversing prior $7.41M operating loss.
Cash Flow Significantly Improved Net cash provided by operating activities totaled $37.31M for nine months, a substantial increase from $6.37M last year.
Net Loss Narrows Nine-month net loss significantly reduced to $13.20M compared to $29.13M reported in the comparable prior period.

リスク要因

Litigation Exposure Remains SentreHEART securityholder complaint alleges breach of contract seeking up to $260,000 plus interest; company vigorously defends.
Minimally Invasive Sales Decline Minimally invasive ablation sales dropped 33.2% in three months as physicians shift away from Hybrid procedures.
Increased R&D Investment Research and development expenses rose 22.0% (9M) due to personnel costs and $5,000K acquired IPR&D milestone payment.
Financing Obligation Created Failed sale-and-leaseback resulted in $6,250K financing obligation; future rental payments are projected through 2030.

見通し

New Pain Management Product Launched cryoICE® cryoXT™ probe in Q3 2025 for Cryo Nerve Block therapy in amputation pain management patients.
Clinical Trial Enrollment Complete LeAAPS IDE trial completed enrollment of 6,500 patients globally; BoxX-NoAF trial enrollment is ongoing.
Enhanced Physician Training Launched innovative training methods including virtual proctoring and new content for Advanced Practice Providers courses.
Tax Legislation Impact New OBBBA legislation made tax cuts permanent; company maintains full valuation allowance on U.S. deferred tax assets.

同業比較

売上高 (TTM)

STAAR Surgical CompanySTAA
$94.91B
+30136.8%
Select Medical Holdings CorporationSEM
$3.93B
-35.0%
QuidelOrtho CorporationQDEL
$2.72B
-3.6%

粗利益率 (最新四半期)

Immunocore Holdings plcIMCR
99.5%
+0.1pp
QuidelOrtho CorporationQDEL
93.2%
+44.7pp
Xeris Biopharma Holdings, Inc.XERS
85.2%
+10.3pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
TWST$3.01B-39.1-16.6%28.8%
TXG$2.42B-31.5-10.3%8.5%
LMAT$2.00B37.415.0%31.0%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
2.6%
緩やかな成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
75%
キャッシュフローの変動が大きい

深度リサーチ

次回決算:2026年2月11日
|
EPS:-$0.04
|
売上高:-
財務レポート
財務データ
全年度
  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年10月30日|
    売上高: $134.27M+15.8%
    |
    EPS: $-0.01-94.1%
    予想を上回る
  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年7月30日|
    売上高: $136.14M+17.1%
    |
    EPS: $-0.13-23.5%
    予想を上回る
  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年4月30日|
    売上高: $123.62M+13.6%
    |
    EPS: $-0.14-50.0%
    予想を上回る
  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月14日|
    売上高: $465.31M+16.5%
    |
    EPS: $-0.95-43.9%
    予想を下回る
  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年10月30日|
    売上高: $115.91M+17.9%
    |
    EPS: $-0.17-15.0%
    予想を上回る
  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年7月31日|
    売上高: $116.27M+15.2%
    |
    EPS: $-0.17+54.5%
    予想を上回る
  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月2日|
    売上高: $108.85M+16.4%
    |
    EPS: $-0.28+100.0%
    予想を下回る
  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年2月16日|
    売上高: $399.25M+20.8%
    |
    EPS: $-0.66+35.3%
    予想を下回る